MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹4,687 Cr | ₹7,420 Cr | ₹187 Cr | ₹199 Cr | ₹169 Cr |
What is the latest Total Non-Current Liabilities ratio of MANKIND PHARMA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹4,687 Cr |
| Mar2025 | ₹7,420 Cr |
| Mar2024 | ₹187 Cr |
| Mar2023 | ₹199 Cr |
| Mar2022 | ₹169 Cr |
How is Total Non-Current Liabilities of MANKIND PHARMA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,687 Cr | -36.84 | |
| Mar2025 | ₹7,420 Cr | 3,860.66 | |
| Mar2024 | ₹187 Cr | -5.97 | |
| Mar2023 | ₹199 Cr | 18.12 | |
| Mar2022 | ₹169 Cr | - | |
Compare Total Non-Current Liabilities of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹100,396.2 Cr | -1.6% | -2.3% | -4.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹466,431.0 Cr | -2.3% | 3% | 12.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹220,115.0 Cr | 2.9% | 22.7% | 25.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,853.0 Cr | -2.7% | 2% | 33.9% | Stock Analytics | |
| CIPLA | ₹119,158.0 Cr | 0.1% | 3% | -7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,074.4 Cr | 2.4% | -12.9% | -9.1% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -1.6% |
-2.3% |
-4.8% |
| SENSEX | 1.3% |
1% |
-2.9% |
You may also like the below Video Courses